Herbal IBS-D Remedy Acts via Fecal Transplant Pathway

A Chinese Herbal Formula’s Success Points to a Fecal Transplant Pathway

Scientists from Shaanxi University of Chinese Medicine have demonstrated how an ancient formula, Da-Jian-Zhong decoction (DJZD), treats diarrhea-predominant irritable bowel syndrome (IBS-D). Their work, published in the Journal of Ethnopharmacology, identified a specific chain of events: the formula reshapes the gut microbiome, which in turn alters bile acid metabolism, ultimately restoring communication along the gut-brain axis. Crucially, they proved that transferring the altered microbiota alone via fecal microbiota transplant (FMT) could replicate the formula’s benefits.

Herbal Treatment and FMT Produce Identical Gut-Brain Improvements

The team led by Gao HQ and Zhang MM first induced IBS-D in rats, resulting in watery stools, heightened pain sensitivity in the colon, and anxious behaviors like reduced exploration in an open field. Treatment with DJZD reversed all these issues: stool form normalized, pain sensitivity dropped, and the animals’ behavior improved. The researchers also measured key gut-brain signaling molecules, finding that DJZD balanced levels of serotonin (5-HT) and substance P in both the colon and the hippocampus, a brain region involved in emotion.

The pivotal experiment came next. The team performed fecal microbiota transplantation, giving untreated IBS-D rats the gut microbes from DJZD-treated donors. The results were striking. FMT alone produced the same full spectrum of improvements as the original herbal treatment. This directly proved that DJZD’s therapeutic effects were mediated primarily through its impact on the gut microbiota. As senior author Ou Li stated, this shows “the regulatory effect of DJZD on the gut-brain axis against IBS-D was dependent on gut microbiota.”

Microbial Bile Acid Metabolism Emerges as the Key Mechanism

To understand how the reshaped microbiome created these changes, the scientists analyzed bile acid profiles. Bile acids, produced by the liver and modified by gut bacteria, are potent signaling molecules. The study found DJZD and the subsequent FMT significantly increased the levels of several secondary bile acids (SBAs), particularly lithocholic acid (LCA) and deoxycholic acid (DCA), along with norchenodeoxycholic acid and 3β-ursodeoxycholic acid.

These SBAs were not coming from the herb itself, but from bacterial metabolism. The increase correlated strongly with a higher abundance of bacteria known to produce specific enzymes: bile salt hydrolases (BSH) and 7α-hydroxysteroid dehydrogenases (7α-HSDH). Key genera identified were Akkermansia, Ruminococcus, and Clostridium. In a final validation, administering a direct mixture of LCA and DCA to IBS-D rats improved intestinal barrier function and gut-brain peptide levels, confirming these specific bile acids as active therapeutic agents in the pathway.

From Rat Model to Human IBS and SIBO Management

While this study was conducted in rats, its findings illuminate potential mechanisms relevant to human FMT and microbiome therapy. It provides a clear model: a successful intervention (herbal or otherwise) enriches specific bile-acid-modifying bacteria. These microbes then produce SBAs that strengthen the gut barrier and normalize gut-brain signaling, alleviating both physical and psychological symptoms. This aligns with the growing understanding of the gut-brain axis in disorders like IBS.

For conditions like SIBO, where bacterial overgrowth disrupts normal metabolism, the research highlights the importance of bacterial function—not just presence. An imbalance in communities like Ruminococcus or Clostridium could impair SBA production, contributing to symptoms. Furthermore, the study suggests that assessing a donor’s bile acid profile, or their microbiome’s functional capacity for SBA production, could be a metric for selecting effective FMT material. It also supports exploring probiotics containing strains with BSH activity as a complementary strategy.

Frequently Asked Questions

Could FMT be a direct treatment for IBS-D?

This study provides strong preclinical evidence that FMT can reverse key symptoms of IBS-D by transferring a functional microbial community. While human FMT for IBS is still largely experimental and regulated, research like this strengthens the scientific rationale for its development.

What are secondary bile acids and why are they important?

Secondary bile acids like LCA and DCA are created when certain gut bacteria metabolize primary bile acids from the liver. They are not waste products; they act as signaling molecules that help maintain intestinal barrier integrity and modulate inflammation, directly influencing gut-brain communication.

Does this mean I should take supplements containing LCA or DCA?

No. Bile acid metabolism is complex and tightly regulated. Direct supplementation could cause significant digestive upset or liver stress. The therapeutic approach suggested by this research is to support the growth of beneficial bacteria that naturally produce these compounds through dietary or probiotic means, under professional guidance.

How does this connect IBS symptoms to anxiety?

The study showed treatment normalized levels of neurotransmitters like serotonin in both the gut and the brain’s hippocampus. This biochemical change, driven by microbial bile acids, was accompanied by improved animal behavior, illustrating a direct biochemical link between the remediated gut environment and mood-related brain regions, a connection explored in our article on the gut-brain axis and depression.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42498089/
https://pubmed.ncbi.nlm.nih.gov/42494851/
https://pubmed.ncbi.nlm.nih.gov/42493518/